logo
logo
MRVI stock ticker logo

Maravai LifeSciences Holdings, Inc.

NASDAQ•MRVI
CEO: Mr. William E. Martin III
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-11-20
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Contact Information
10770 Wateridge Circle, Suite 200, San Diego, CA, 92121, United States
858-546-0004
www.maravai.com
Market Cap
$846.23M
P/E (TTM)
-3.4
17.9
Dividend Yield
--
52W High
$4.11
52W Low
$1.67
52W Range
58%
Rank40Top 42.0%
4.1
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Average • 4.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$49.87M+0.00%
4-Quarter Trend

EPS

-$0.25+0.00%
4-Quarter Trend

FCF

-$24.88M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Decline Post-Vaccine Sales Total revenue $185.7M, down 28.3% from 2024; CleanCap vaccine sales absent in 2025 impacting top line.
Profitability Deterioration Noted Gross profit $34.0M, down 68.6%; Adjusted EBITDA $(31.2)M versus $35.9M profit recorded in prior year.
Major Asset Impairments Recorded Recorded $42.9M goodwill impairment across reporting units; $25.8M intangible asset impairment also recognized.
Workforce Realignment Implemented Implemented 2025 Realignment Plan, terminating 25% workforce; targeting over $65.0M in annualized expense savings.

Risk Factors

High Vaccine Revenue Dependency Revenue highly dependent on unpredictable commercial vaccine programs; 2025 sales were 0.0% of total revenue.
Sharp Gross Margin Contraction Gross margin fell sharply to 18.3% from 41.8%; higher facility and depreciation costs pressured profitability.
Competition Threatens Obsolescence Face competition from larger, better-resourced life science companies developing potentially obsolete product approaches.
Supplier Reliance Poses Risk Reliance on limited or sole suppliers for critical raw materials; supply chain disruptions pose a material operational risk.

Outlook

Restructuring Completion Focus Completing 2025 Corporate Realignment Plan phased approach by Q3 2026; aiming for sustained cost structure alignment.
Core Segment Resource Focus Focusing resources on core TriLink and Cygnus segments; Cygnus revenue showed 5.0% growth in the current year.
Liquidity Position Remains Strong Cash position robust at $216.9M end 2025; funds allocated for operations, debt repayment, and recent acquisitions.
Stabilizing Post Leadership Change New CEO/CFO appointed in 2025; focus on stabilizing operations following leadership transition and realignment actions.

Peer Comparison

Revenue (TTM)

IOVA stock ticker logoIOVA
$263.50M
+60.6%
MRVI stock ticker logoMRVI
$185.74M
-28.3%
PHAT stock ticker logoPHAT
$175.11M
+216.9%

Gross Margin (Latest Quarter)

PRME stock ticker logoPRME
4698.2%
-3591.0pp
VIR stock ticker logoVIR
672.1%
-54902.1pp
IOVA stock ticker logoIOVA
215.9%
+65.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TYRA$1.95B-18.0-41.2%2.1%
IOVA$1.31B-4.1-54.5%5.3%
VIR$1.29B-2.9-49.3%18.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:Mar 17, 2026
|
EPS:-$0.07
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data